You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDeslanoside
Accession NumberDB01078  (APRD00909)
TypeSmall Molecule
GroupsApproved
DescriptionDeacetyllanatoside C. A cardiotonic glycoside from the leaves of Digitalis lanata. [PubChem]
Structure
Thumb
Synonyms
(3beta,5beta,12beta)-3-{[beta-D-glucopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide
3-[(O-beta-D-Glucopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-3beta,5beta,12beta-card-20(22)-enolide
Deacetyllanatoside C
Desacetyllanatoside C
Deslanosido
Deslanosidum
Glucodigoxin
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Cedilanid-dNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIYGY317RK75
CAS number17598-65-1
WeightAverage: 943.0791
Monoisotopic: 942.482430186
Chemical FormulaC47H74O19
InChI KeyInChIKey=OBATZBGFDSVCJD-LALPQLPRSA-N
InChI
InChI=1S/C47H74O19/c1-20-41(64-36-16-30(50)42(21(2)60-36)65-37-17-31(51)43(22(3)61-37)66-44-40(56)39(55)38(54)32(18-48)63-44)29(49)15-35(59-20)62-25-8-10-45(4)24(13-25)6-7-27-28(45)14-33(52)46(5)26(9-11-47(27,46)57)23-12-34(53)58-19-23/h12,20-22,24-33,35-44,48-52,54-57H,6-11,13-19H2,1-5H3/t20-,21-,22-,24-,25+,26-,27-,28+,29+,30+,31+,32-,33-,35+,36+,37+,38-,39+,40-,41-,42-,43-,44+,45+,46+,47+/m1/s1
IUPAC Name
4-[(1S,2S,5S,7R,10R,11S,14R,15S,16R)-11,16-dihydroxy-5-{[(2R,4S,5S,6R)-4-hydroxy-5-{[(2S,4S,5S,6R)-4-hydroxy-5-{[(2S,4S,5S,6R)-4-hydroxy-6-methyl-5-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-14-yl]-2,5-dihydrofuran-2-one
SMILES
C[[email protected]]1O[[email protected]](C[[email protected]](O)[C@@H]1O[[email protected]]1C[[email protected]](O)[[email protected]](O[[email protected]]2C[[email protected]](O)[[email protected]](O[C@@H]3O[[email protected]](CO)[C@@H](O)[[email protected]](O)[[email protected]]3O)[C@@H](C)O2)[C@@H](C)O1)O[[email protected]]1CC[C@@]2(C)[[email protected]](CC[C@@H]3[C@@H]2C[C@@H](O)[C@]2(C)[[email protected]](CC[C@]32O)C2=CC(=O)OC2)C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as cardenolide glycosides and derivatives. These are compounds containing a carbohydrate glycosidically bound to the cardenolide moiety.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassSteroid lactones
Direct ParentCardenolide glycosides and derivatives
Alternative Parents
Substituents
  • Cardanolide-glycoside
  • Steroidal glycoside
  • Oligosaccharide
  • Hydroxysteroid
  • 12-hydroxysteroid
  • O-glycosyl compound
  • Glycosyl compound
  • Oxane
  • Saccharide
  • 2-furanone
  • Alpha,beta-unsaturated carboxylic ester
  • Enoate ester
  • Tertiary alcohol
  • Dihydrofuran
  • Cyclic alcohol
  • Secondary alcohol
  • Polyol
  • Lactone
  • Carboxylic acid ester
  • 1,2-diol
  • Oxacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Carboxylic acid derivative
  • Acetal
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Carbonyl group
  • Alcohol
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment and management of Congestive cardiac insufficiency, arrhythmias and heart failure.
PharmacodynamicsDeslanoside is a cardiac glycoside used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation.
Mechanism of actionDeslanoside inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). Deslanoside also acts on the electrical activity of the heart, increasing the slope of phase 4 depolarization, shortening the action potential duration, and decreasing the maximal diastolic potential.
Related Articles
AbsorptionLittle absorption from the gastrointestinal tract (40%).
Volume of distributionNot Available
Protein binding20%
MetabolismNot Available
Route of eliminationNot Available
Half life36 hours
ClearanceNot Available
ToxicitySymptoms of overdose include ventricular tachycardia, ventricular fibrillation, progressive bradyarrhythmias, or heart block.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8985
Blood Brain Barrier-0.5781
Caco-2 permeable-0.924
P-glycoprotein substrateSubstrate0.8738
P-glycoprotein inhibitor IInhibitor0.5533
P-glycoprotein inhibitor IIInhibitor0.6189
Renal organic cation transporterNon-inhibitor0.8371
CYP450 2C9 substrateNon-substrate0.8483
CYP450 2D6 substrateNon-substrate0.8905
CYP450 3A4 substrateSubstrate0.7052
CYP450 1A2 substrateNon-inhibitor0.9197
CYP450 2C9 inhibitorNon-inhibitor0.9182
CYP450 2D6 inhibitorNon-inhibitor0.938
CYP450 2C19 inhibitorNon-inhibitor0.9284
CYP450 3A4 inhibitorNon-inhibitor0.9194
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9237
Ames testNon AMES toxic0.9309
CarcinogenicityNon-carcinogens0.9583
BiodegradationNot ready biodegradable0.9845
Rat acute toxicity4.9815 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9515
hERG inhibition (predictor II)Inhibitor0.8395
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP0.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.468 mg/mLALOGPS
logP-0.49ALOGPS
logP0.6ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)7.15ChemAxon
pKa (Strongest Basic)-3.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count18ChemAxon
Hydrogen Donor Count9ChemAxon
Polar Surface Area282.21 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity225.65 m3·mol-1ChemAxon
Polarizability100.65 Å3ChemAxon
Number of Rings9ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesC01AA07
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
2-(4-Chlorophenyl)-5-QuinoxalinecarboxamideDeslanoside may decrease the cardiotoxic activities of 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide.
2-MethoxyestradiolDeslanoside may decrease the cardiotoxic activities of 2-Methoxyestradiol.
3-MethoxybenzamideDeslanoside may decrease the cardiotoxic activities of 3-Methoxybenzamide.
3,4-Dihydroxybenzoic AcidDeslanoside may decrease the cardiotoxic activities of 3,4-Dihydroxybenzoic Acid.
5,10-Dideazatetrahydrofolic AcidDeslanoside may decrease the cardiotoxic activities of 5,10-Dideazatetrahydrofolic Acid.
7-HydroxystaurosporineDeslanoside may decrease the cardiotoxic activities of 7-Hydroxystaurosporine.
8-azaguanineDeslanoside may decrease the cardiotoxic activities of 8-azaguanine.
9-(2-phosphonylmethoxyethyl)-2,6-diaminopurineDeslanoside may decrease the cardiotoxic activities of 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine.
AbirateroneDeslanoside may decrease the cardiotoxic activities of Abiraterone.
ABT-263Deslanoside may decrease the cardiotoxic activities of ABT-263.
AcebutololAcebutolol may increase the bradycardic activities of Deslanoside.
AfatinibDeslanoside may decrease the cardiotoxic activities of Afatinib.
AfimoxifeneDeslanoside may decrease the cardiotoxic activities of Afimoxifene.
AfliberceptDeslanoside may decrease the cardiotoxic activities of Aflibercept.
AlatrofloxacinDeslanoside may decrease the cardiotoxic activities of Alatrofloxacin.
AlbendazoleDeslanoside may decrease the cardiotoxic activities of Albendazole.
AldesleukinDeslanoside may decrease the cardiotoxic activities of Aldesleukin.
AlemtuzumabDeslanoside may decrease the cardiotoxic activities of Alemtuzumab.
AlitretinoinDeslanoside may decrease the cardiotoxic activities of Alitretinoin.
Alpha-DifluoromethylornithineDeslanoside may decrease the cardiotoxic activities of Alpha-Difluoromethylornithine.
AlprenololAlprenolol may increase the bradycardic activities of Deslanoside.
AltretamineDeslanoside may decrease the cardiotoxic activities of Altretamine.
AmikacinThe serum concentration of Deslanoside can be decreased when it is combined with Amikacin.
AmilorideThe therapeutic efficacy of Deslanoside can be decreased when used in combination with Amiloride.
AminoglutethimideDeslanoside may decrease the cardiotoxic activities of Aminoglutethimide.
Aminolevulinic acidDeslanoside may decrease the cardiotoxic activities of Aminolevulinic acid.
AmiodaroneThe serum concentration of Deslanoside can be increased when it is combined with Amiodarone.
AmodiaquineThe serum concentration of Deslanoside can be increased when it is combined with Amodiaquine.
AmonafideDeslanoside may decrease the cardiotoxic activities of Amonafide.
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Deslanoside.
AmrubicinDeslanoside may decrease the cardiotoxic activities of Amrubicin.
AmsacrineDeslanoside may decrease the cardiotoxic activities of Amsacrine.
AnagrelideDeslanoside may decrease the cardiotoxic activities of Anagrelide.
AnastrozoleDeslanoside may decrease the cardiotoxic activities of Anastrozole.
annamycinDeslanoside may decrease the cardiotoxic activities of annamycin.
AP 12009Deslanoside may decrease the cardiotoxic activities of AP 12009.
AP24534Deslanoside may decrease the cardiotoxic activities of AP24534.
ArotinololArotinolol may increase the bradycardic activities of Deslanoside.
Arsenic trioxideDeslanoside may decrease the cardiotoxic activities of Arsenic trioxide.
ASA404Deslanoside may decrease the cardiotoxic activities of ASA404.
AsparaginaseDeslanoside may decrease the cardiotoxic activities of Asparaginase.
AT-101Deslanoside may decrease the cardiotoxic activities of AT-101.
AtenololAtenolol may increase the bradycardic activities of Deslanoside.
AxitinibDeslanoside may decrease the cardiotoxic activities of Axitinib.
AzacitidineDeslanoside may decrease the cardiotoxic activities of Azacitidine.
AzathioprineDeslanoside may decrease the cardiotoxic activities of Azathioprine.
AZD2171Deslanoside may decrease the cardiotoxic activities of AZD2171.
Azelaic AcidDeslanoside may decrease the cardiotoxic activities of Azelaic Acid.
BalsalazideThe serum concentration of Deslanoside can be decreased when it is combined with Balsalazide.
BatimastatDeslanoside may decrease the cardiotoxic activities of Batimastat.
BefunololBefunolol may increase the bradycardic activities of Deslanoside.
BelinostatDeslanoside may decrease the cardiotoxic activities of Belinostat.
BendamustineDeslanoside may decrease the cardiotoxic activities of Bendamustine.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Deslanoside.
BesifloxacinDeslanoside may decrease the cardiotoxic activities of Besifloxacin.
BetaxololBetaxolol may increase the bradycardic activities of Deslanoside.
BevacizumabDeslanoside may decrease the cardiotoxic activities of Bevacizumab.
BevantololBevantolol may increase the bradycardic activities of Deslanoside.
BexaroteneDeslanoside may decrease the cardiotoxic activities of Bexarotene.
BicalutamideDeslanoside may decrease the cardiotoxic activities of Bicalutamide.
BisoprololBisoprolol may increase the bradycardic activities of Deslanoside.
BleomycinDeslanoside may decrease the cardiotoxic activities of Bleomycin.
BlinatumomabDeslanoside may decrease the cardiotoxic activities of Blinatumomab.
BopindololBopindolol may increase the bradycardic activities of Deslanoside.
BortezomibDeslanoside may decrease the cardiotoxic activities of Bortezomib.
BosutinibDeslanoside may decrease the cardiotoxic activities of Bosutinib.
Brentuximab vedotinDeslanoside may decrease the cardiotoxic activities of Brentuximab vedotin.
BSI-201Deslanoside may decrease the cardiotoxic activities of BSI-201.
BufuralolBufuralol may increase the bradycardic activities of Deslanoside.
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Deslanoside.
BupranololBupranolol may increase the bradycardic activities of Deslanoside.
BusulfanDeslanoside may decrease the cardiotoxic activities of Busulfan.
CabazitaxelDeslanoside may decrease the cardiotoxic activities of Cabazitaxel.
CabergolineDeslanoside may decrease the cardiotoxic activities of Cabergoline.
CabozantinibDeslanoside may decrease the cardiotoxic activities of Cabozantinib.
CalcipotriolDeslanoside may decrease the cardiotoxic activities of Calcipotriol.
CamptothecinDeslanoside may decrease the cardiotoxic activities of Camptothecin.
CapecitabineDeslanoside may decrease the cardiotoxic activities of Capecitabine.
CarbimazoleThe serum concentration of Deslanoside can be increased when it is combined with Carbimazole.
CarboplatinDeslanoside may decrease the cardiotoxic activities of Carboplatin.
CarfilzomibDeslanoside may decrease the cardiotoxic activities of Carfilzomib.
CarmofurDeslanoside may decrease the cardiotoxic activities of Carmofur.
CarmustineDeslanoside may decrease the cardiotoxic activities of Carmustine.
CarteololCarteolol may increase the bradycardic activities of Deslanoside.
CarvedilolCarvedilol may increase the bradycardic activities of Deslanoside.
CatumaxomabDeslanoside may decrease the cardiotoxic activities of Catumaxomab.
CB1954Deslanoside may decrease the cardiotoxic activities of CB1954.
CelecoxibDeslanoside may decrease the cardiotoxic activities of Celecoxib.
CeliprololCeliprolol may increase the bradycardic activities of Deslanoside.
CeritinibDeslanoside may decrease the cardiotoxic activities of Ceritinib.
CetuximabDeslanoside may decrease the cardiotoxic activities of Cetuximab.
ChlorambucilDeslanoside may decrease the cardiotoxic activities of Chlorambucil.
ChloroquineThe serum concentration of Deslanoside can be increased when it is combined with Chloroquine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Deslanoside.
ChlorotrianiseneDeslanoside may decrease the cardiotoxic activities of Chlorotrianisene.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Deslanoside.
CholestyramineCholestyramine can cause a decrease in the absorption of Deslanoside resulting in a reduced serum concentration and potentially a decrease in efficacy.
CinoxacinDeslanoside may decrease the cardiotoxic activities of Cinoxacin.
CiprofloxacinDeslanoside may decrease the cardiotoxic activities of Ciprofloxacin.
CisplatinDeslanoside may decrease the cardiotoxic activities of Cisplatin.
CladribineDeslanoside may decrease the cardiotoxic activities of Cladribine.
ClofarabineDeslanoside may decrease the cardiotoxic activities of Clofarabine.
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Deslanoside.
ColchicineDeslanoside may decrease the cardiotoxic activities of Colchicine.
ColesevelamColesevelam can cause a decrease in the absorption of Deslanoside resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Deslanoside resulting in a reduced serum concentration and potentially a decrease in efficacy.
CrizotinibDeslanoside may decrease the cardiotoxic activities of Crizotinib.
CyclophosphamideDeslanoside may decrease the cardiotoxic activities of Cyclophosphamide.
Cyproterone acetateDeslanoside may decrease the cardiotoxic activities of Cyproterone acetate.
CytarabineDeslanoside may decrease the cardiotoxic activities of Cytarabine.
DabrafenibDeslanoside may decrease the cardiotoxic activities of Dabrafenib.
DacarbazineDeslanoside may decrease the cardiotoxic activities of Dacarbazine.
DactinomycinDeslanoside may decrease the cardiotoxic activities of Dactinomycin.
DaratumumabDeslanoside may decrease the cardiotoxic activities of Daratumumab.
DasatinibDeslanoside may decrease the cardiotoxic activities of Dasatinib.
DaunorubicinDeslanoside may decrease the cardiotoxic activities of Daunorubicin.
DaunorubicinThe serum concentration of Deslanoside can be decreased when it is combined with Daunorubicin.
DecitabineDeslanoside may decrease the cardiotoxic activities of Decitabine.
Denileukin diftitoxDeslanoside may decrease the cardiotoxic activities of Denileukin diftitox.
DexamethasoneDeslanoside may decrease the cardiotoxic activities of Dexamethasone.
DexrazoxaneDeslanoside may decrease the cardiotoxic activities of Dexrazoxane.
DienogestDeslanoside may decrease the cardiotoxic activities of Dienogest.
DiethylstilbestrolDeslanoside may decrease the cardiotoxic activities of Diethylstilbestrol.
DihydrostreptomycinThe serum concentration of Deslanoside can be decreased when it is combined with Dihydrostreptomycin.
DinutuximabDeslanoside may decrease the cardiotoxic activities of Dinutuximab.
DocetaxelDeslanoside may decrease the cardiotoxic activities of Docetaxel.
DoxorubicinDeslanoside may decrease the cardiotoxic activities of Doxorubicin.
DoxorubicinThe serum concentration of Deslanoside can be decreased when it is combined with Doxorubicin.
EcabetDeslanoside may decrease the cardiotoxic activities of Ecabet.
EdrophoniumEdrophonium may increase the atrioventricular blocking (AV block) activities of Deslanoside.
efaproxiralDeslanoside may decrease the cardiotoxic activities of efaproxiral.
EflornithineDeslanoside may decrease the cardiotoxic activities of Eflornithine.
EG009Deslanoside may decrease the cardiotoxic activities of EG009.
ElsamitrucinDeslanoside may decrease the cardiotoxic activities of Elsamitrucin.
EndostatinDeslanoside may decrease the cardiotoxic activities of Endostatin.
EnoxacinDeslanoside may decrease the cardiotoxic activities of Enoxacin.
EnrofloxacinDeslanoside may decrease the cardiotoxic activities of Enrofloxacin.
EpirubicinDeslanoside may decrease the cardiotoxic activities of Epirubicin.
EpirubicinThe serum concentration of Deslanoside can be decreased when it is combined with Epirubicin.
EplerenoneThe therapeutic efficacy of Deslanoside can be decreased when used in combination with Eplerenone.
Epothilone BDeslanoside may decrease the cardiotoxic activities of Epothilone B.
EribulinDeslanoside may decrease the cardiotoxic activities of Eribulin.
ErlotinibDeslanoside may decrease the cardiotoxic activities of Erlotinib.
EsmololEsmolol may increase the bradycardic activities of Deslanoside.
EstramustineDeslanoside may decrease the cardiotoxic activities of Estramustine.
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Deslanoside.
Ethiodized oilDeslanoside may decrease the cardiotoxic activities of Ethiodized oil.
Ethyl carbamateDeslanoside may decrease the cardiotoxic activities of Ethyl carbamate.
EtoposideDeslanoside may decrease the cardiotoxic activities of Etoposide.
EverolimusDeslanoside may decrease the cardiotoxic activities of Everolimus.
ExemestaneDeslanoside may decrease the cardiotoxic activities of Exemestane.
exisulindDeslanoside may decrease the cardiotoxic activities of exisulind.
FenretinideDeslanoside may decrease the cardiotoxic activities of Fenretinide.
FlavopiridolDeslanoside may decrease the cardiotoxic activities of Flavopiridol.
FleroxacinDeslanoside may decrease the cardiotoxic activities of Fleroxacin.
FloxuridineDeslanoside may decrease the cardiotoxic activities of Floxuridine.
FludarabineDeslanoside may decrease the cardiotoxic activities of Fludarabine.
FlumequineDeslanoside may decrease the cardiotoxic activities of Flumequine.
FluorouracilDeslanoside may decrease the cardiotoxic activities of Fluorouracil.
FlutamideDeslanoside may decrease the cardiotoxic activities of Flutamide.
FormestaneDeslanoside may decrease the cardiotoxic activities of Formestane.
FormycinDeslanoside may decrease the cardiotoxic activities of Formycin.
FotemustineDeslanoside may decrease the cardiotoxic activities of Fotemustine.
FramycetinThe serum concentration of Deslanoside can be decreased when it is combined with Framycetin.
FulvestrantDeslanoside may decrease the cardiotoxic activities of Fulvestrant.
FumagillinDeslanoside may decrease the cardiotoxic activities of Fumagillin.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Deslanoside.
Gallium nitrateDeslanoside may decrease the cardiotoxic activities of Gallium nitrate.
GarenoxacinDeslanoside may decrease the cardiotoxic activities of Garenoxacin.
GatifloxacinDeslanoside may decrease the cardiotoxic activities of Gatifloxacin.
GefitinibDeslanoside may decrease the cardiotoxic activities of Gefitinib.
GeldanamycinDeslanoside may decrease the cardiotoxic activities of Geldanamycin.
GemcitabineDeslanoside may decrease the cardiotoxic activities of Gemcitabine.
GemifloxacinDeslanoside may decrease the cardiotoxic activities of Gemifloxacin.
Gemtuzumab ozogamicinDeslanoside may decrease the cardiotoxic activities of Gemtuzumab ozogamicin.
GenisteinDeslanoside may decrease the cardiotoxic activities of Genistein.
GentamicinThe serum concentration of Deslanoside can be decreased when it is combined with Gentamicin.
Ginsenoside CDeslanoside may decrease the cardiotoxic activities of Ginsenoside C.
GoserelinDeslanoside may decrease the cardiotoxic activities of Goserelin.
GrepafloxacinDeslanoside may decrease the cardiotoxic activities of Grepafloxacin.
HadacidinDeslanoside may decrease the cardiotoxic activities of Hadacidin.
HalofuginoneDeslanoside may decrease the cardiotoxic activities of Halofuginone.
HexestrolDeslanoside may decrease the cardiotoxic activities of Hexestrol.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Deslanoside.
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Deslanoside.
HydroxychloroquineThe serum concentration of Deslanoside can be increased when it is combined with Hydroxychloroquine.
Hydroxyprogesterone caproateDeslanoside may decrease the cardiotoxic activities of Hydroxyprogesterone caproate.
HydroxyureaDeslanoside may decrease the cardiotoxic activities of Hydroxyurea.
Hygromycin BThe serum concentration of Deslanoside can be decreased when it is combined with Hygromycin B.
IbrutinibDeslanoside may decrease the cardiotoxic activities of Ibrutinib.
IdarubicinDeslanoside may decrease the cardiotoxic activities of Idarubicin.
IdarubicinThe serum concentration of Deslanoside can be decreased when it is combined with Idarubicin.
IdelalisibDeslanoside may decrease the cardiotoxic activities of Idelalisib.
IfosfamideDeslanoside may decrease the cardiotoxic activities of Ifosfamide.
ImatinibDeslanoside may decrease the cardiotoxic activities of Imatinib.
ImiquimodDeslanoside may decrease the cardiotoxic activities of Imiquimod.
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Deslanoside.
IndenololIndenolol may increase the bradycardic activities of Deslanoside.
Interferon beta-1aDeslanoside may decrease the cardiotoxic activities of Interferon beta-1a.
IobenguaneDeslanoside may decrease the cardiotoxic activities of Iobenguane.
IpilimumabDeslanoside may decrease the cardiotoxic activities of Ipilimumab.
IrinotecanDeslanoside may decrease the cardiotoxic activities of Irinotecan.
ItraconazoleThe serum concentration of Deslanoside can be increased when it is combined with Itraconazole.
IxabepiloneDeslanoside may decrease the cardiotoxic activities of Ixabepilone.
IxazomibDeslanoside may decrease the cardiotoxic activities of Ixazomib.
KanamycinThe serum concentration of Deslanoside can be decreased when it is combined with Kanamycin.
KaolinThe serum concentration of Deslanoside can be decreased when it is combined with Kaolin.
KOS-1584Deslanoside may decrease the cardiotoxic activities of KOS-1584.
L-alanosineDeslanoside may decrease the cardiotoxic activities of L-alanosine.
LabetalolLabetalol may increase the bradycardic activities of Deslanoside.
LanreotideDeslanoside may decrease the cardiotoxic activities of Lanreotide.
LapatinibDeslanoside may decrease the cardiotoxic activities of Lapatinib.
LeflunomideDeslanoside may decrease the cardiotoxic activities of Leflunomide.
LenalidomideDeslanoside may decrease the cardiotoxic activities of Lenalidomide.
LenvatinibDeslanoside may decrease the cardiotoxic activities of Lenvatinib.
LetrozoleDeslanoside may decrease the cardiotoxic activities of Letrozole.
LeuprolideDeslanoside may decrease the cardiotoxic activities of Leuprolide.
LevobunololLevobunolol may increase the bradycardic activities of Deslanoside.
LevofloxacinDeslanoside may decrease the cardiotoxic activities of Levofloxacin.
LicoriceThe risk or severity of adverse effects can be increased when Licorice is combined with Deslanoside.
LomefloxacinDeslanoside may decrease the cardiotoxic activities of Lomefloxacin.
LomustineDeslanoside may decrease the cardiotoxic activities of Lomustine.
LonidamineDeslanoside may decrease the cardiotoxic activities of Lonidamine.
LycopeneDeslanoside may decrease the cardiotoxic activities of Lycopene.
MasitinibDeslanoside may decrease the cardiotoxic activities of Masitinib.
MasoprocolDeslanoside may decrease the cardiotoxic activities of Masoprocol.
MaxacalcitolDeslanoside may decrease the cardiotoxic activities of Maxacalcitol.
MDX-1106Deslanoside may decrease the cardiotoxic activities of MDX-1106.
MebendazoleDeslanoside may decrease the cardiotoxic activities of Mebendazole.
MechlorethamineDeslanoside may decrease the cardiotoxic activities of Mechlorethamine.
MedrogestoneDeslanoside may decrease the cardiotoxic activities of Medrogestone.
Medroxyprogesterone acetateDeslanoside may decrease the cardiotoxic activities of Medroxyprogesterone acetate.
Megestrol acetateDeslanoside may decrease the cardiotoxic activities of Megestrol acetate.
MelphalanDeslanoside may decrease the cardiotoxic activities of Melphalan.
MequinolDeslanoside may decrease the cardiotoxic activities of Mequinol.
MercaptopurineDeslanoside may decrease the cardiotoxic activities of Mercaptopurine.
MesalazineThe serum concentration of Deslanoside can be decreased when it is combined with Mesalazine.
MethimazoleThe serum concentration of Deslanoside can be increased when it is combined with Methimazole.
MethotrexateDeslanoside may decrease the cardiotoxic activities of Methotrexate.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Deslanoside.
Methyl aminolevulinateDeslanoside may decrease the cardiotoxic activities of Methyl aminolevulinate.
MethylprednisoloneDeslanoside may decrease the cardiotoxic activities of Methylprednisolone.
MethyltestosteroneDeslanoside may decrease the cardiotoxic activities of Methyltestosterone.
MetipranololMetipranolol may increase the bradycardic activities of Deslanoside.
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Deslanoside.
MetoprololMetoprolol may increase the bradycardic activities of Deslanoside.
MetrizamideThe serum concentration of Deslanoside can be decreased when it is combined with Metrizamide.
MGI-114Deslanoside may decrease the cardiotoxic activities of MGI-114.
MidodrineDeslanoside may increase the bradycardic activities of Midodrine.
MidostaurinDeslanoside may decrease the cardiotoxic activities of Midostaurin.
MiltefosineDeslanoside may decrease the cardiotoxic activities of Miltefosine.
MitomycinDeslanoside may decrease the cardiotoxic activities of Mitomycin.
MitotaneDeslanoside may decrease the cardiotoxic activities of Mitotane.
MitoxantroneDeslanoside may decrease the cardiotoxic activities of Mitoxantrone.
motexafin gadoliniumDeslanoside may decrease the cardiotoxic activities of motexafin gadolinium.
MoxifloxacinDeslanoside may decrease the cardiotoxic activities of Moxifloxacin.
Mycophenolic acidDeslanoside may decrease the cardiotoxic activities of Mycophenolic acid.
NadololNadolol may increase the bradycardic activities of Deslanoside.
Nalidixic AcidDeslanoside may decrease the cardiotoxic activities of Nalidixic Acid.
NecitumumabDeslanoside may decrease the cardiotoxic activities of Necitumumab.
NelarabineDeslanoside may decrease the cardiotoxic activities of Nelarabine.
NeomycinThe serum concentration of Deslanoside can be decreased when it is combined with Neomycin.
NetilmicinThe serum concentration of Deslanoside can be decreased when it is combined with Netilmicin.
NiguldipineDeslanoside may decrease the cardiotoxic activities of Niguldipine.
NilotinibDeslanoside may decrease the cardiotoxic activities of Nilotinib.
NilutamideDeslanoside may decrease the cardiotoxic activities of Nilutamide.
NintedanibDeslanoside may decrease the cardiotoxic activities of Nintedanib.
NivolumabDeslanoside may decrease the cardiotoxic activities of Nivolumab.
nocodazoleDeslanoside may decrease the cardiotoxic activities of nocodazole.
NorfloxacinDeslanoside may decrease the cardiotoxic activities of Norfloxacin.
ObinutuzumabDeslanoside may decrease the cardiotoxic activities of Obinutuzumab.
OctreotideDeslanoside may decrease the cardiotoxic activities of Octreotide.
OfatumumabDeslanoside may decrease the cardiotoxic activities of Ofatumumab.
OfloxacinDeslanoside may decrease the cardiotoxic activities of Ofloxacin.
OlaparibDeslanoside may decrease the cardiotoxic activities of Olaparib.
OlsalazineThe serum concentration of Deslanoside can be decreased when it is combined with Olsalazine.
Omacetaxine mepesuccinateDeslanoside may decrease the cardiotoxic activities of Omacetaxine mepesuccinate.
OprelvekinDeslanoside may decrease the cardiotoxic activities of Oprelvekin.
OsimertinibDeslanoside may decrease the cardiotoxic activities of Osimertinib.
OxaliplatinDeslanoside may decrease the cardiotoxic activities of Oxaliplatin.
OxprenololOxprenolol may increase the bradycardic activities of Deslanoside.
PaclitaxelDeslanoside may decrease the cardiotoxic activities of Paclitaxel.
PalbociclibDeslanoside may decrease the cardiotoxic activities of Palbociclib.
PalifosfamideDeslanoside may decrease the cardiotoxic activities of Palifosfamide.
PamidronateDeslanoside may decrease the cardiotoxic activities of Pamidronate.
PanitumumabDeslanoside may decrease the cardiotoxic activities of Panitumumab.
PanobinostatDeslanoside may decrease the cardiotoxic activities of Panobinostat.
Parathyroid hormoneThe risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Deslanoside.
ParomomycinThe serum concentration of Deslanoside can be decreased when it is combined with Paromomycin.
PazopanibDeslanoside may decrease the cardiotoxic activities of Pazopanib.
PefloxacinDeslanoside may decrease the cardiotoxic activities of Pefloxacin.
PegaspargaseDeslanoside may decrease the cardiotoxic activities of Pegaspargase.
PembrolizumabDeslanoside may decrease the cardiotoxic activities of Pembrolizumab.
PemetrexedDeslanoside may decrease the cardiotoxic activities of Pemetrexed.
PenbutololPenbutolol may increase the bradycardic activities of Deslanoside.
PentostatinDeslanoside may decrease the cardiotoxic activities of Pentostatin.
PertuzumabDeslanoside may decrease the cardiotoxic activities of Pertuzumab.
Phenylacetic acidDeslanoside may decrease the cardiotoxic activities of Phenylacetic acid.
PindololPindolol may increase the bradycardic activities of Deslanoside.
PipobromanDeslanoside may decrease the cardiotoxic activities of Pipobroman.
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Deslanoside.
PirfenidoneDeslanoside may decrease the cardiotoxic activities of Pirfenidone.
PirlindoleDeslanoside may decrease the cardiotoxic activities of Pirlindole.
PixantroneDeslanoside may decrease the cardiotoxic activities of Pixantrone.
PlicamycinDeslanoside may decrease the cardiotoxic activities of Plicamycin.
PlicamycinThe serum concentration of Deslanoside can be decreased when it is combined with Plicamycin.
PodofiloxDeslanoside may decrease the cardiotoxic activities of Podofilox.
PodophyllinDeslanoside may decrease the cardiotoxic activities of Podophyllin.
polyacrylic acidDeslanoside may decrease the cardiotoxic activities of polyacrylic acid.
Polystyrene sulfonateThe risk or severity of adverse effects can be increased when Polystyrene sulfonate is combined with Deslanoside.
PolythiazideThe risk or severity of adverse effects can be increased when Polythiazide is combined with Deslanoside.
PomalidomideDeslanoside may decrease the cardiotoxic activities of Pomalidomide.
PonatinibDeslanoside may decrease the cardiotoxic activities of Ponatinib.
PorfimerDeslanoside may decrease the cardiotoxic activities of Porfimer.
porfiromycinDeslanoside may decrease the cardiotoxic activities of porfiromycin.
PractololPractolol may increase the bradycardic activities of Deslanoside.
PralatrexateDeslanoside may decrease the cardiotoxic activities of Pralatrexate.
PrednisoloneDeslanoside may decrease the cardiotoxic activities of Prednisolone.
PrednisoneDeslanoside may decrease the cardiotoxic activities of Prednisone.
PrimaquineThe serum concentration of Deslanoside can be increased when it is combined with Primaquine.
ProcarbazineDeslanoside may decrease the cardiotoxic activities of Procarbazine.
PropafenoneThe serum concentration of Deslanoside can be increased when it is combined with Propafenone.
PropranololPropranolol may increase the bradycardic activities of Deslanoside.
PropylthiouracilThe serum concentration of Deslanoside can be increased when it is combined with Propylthiouracil.
Purine RibosideDeslanoside may decrease the cardiotoxic activities of Purine Riboside.
PuromycinDeslanoside may decrease the cardiotoxic activities of Puromycin.
PuromycinThe serum concentration of Deslanoside can be decreased when it is combined with Puromycin.
QuinacrineDeslanoside may decrease the cardiotoxic activities of Quinacrine.
QuinethazoneThe risk or severity of adverse effects can be increased when Quinethazone is combined with Deslanoside.
QuinidineThe serum concentration of Deslanoside can be increased when it is combined with Quinidine.
Radium Ra 223 DichlorideDeslanoside may decrease the cardiotoxic activities of Radium Ra 223 Dichloride.
RaltitrexedDeslanoside may decrease the cardiotoxic activities of Raltitrexed.
RamucirumabDeslanoside may decrease the cardiotoxic activities of Ramucirumab.
RanibizumabDeslanoside may decrease the cardiotoxic activities of Ranibizumab.
RanpirnaseDeslanoside may decrease the cardiotoxic activities of Ranpirnase.
RegorafenibDeslanoside may decrease the cardiotoxic activities of Regorafenib.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Deslanoside.
ResveratrolDeslanoside may decrease the cardiotoxic activities of Resveratrol.
Rhodamine 6GDeslanoside may decrease the cardiotoxic activities of Rhodamine 6G.
RibostamycinThe serum concentration of Deslanoside can be decreased when it is combined with Ribostamycin.
RituximabDeslanoside may decrease the cardiotoxic activities of Rituximab.
RomidepsinDeslanoside may decrease the cardiotoxic activities of Romidepsin.
RomiplostimDeslanoside may decrease the cardiotoxic activities of Romiplostim.
RoquinimexDeslanoside may decrease the cardiotoxic activities of Roquinimex.
RubitecanDeslanoside may decrease the cardiotoxic activities of Rubitecan.
RuxolitinibDeslanoside may decrease the cardiotoxic activities of Ruxolitinib.
SatraplatinDeslanoside may decrease the cardiotoxic activities of Satraplatin.
SeliciclibDeslanoside may decrease the cardiotoxic activities of Seliciclib.
SemaxanibDeslanoside may decrease the cardiotoxic activities of Semaxanib.
SeocalcitolDeslanoside may decrease the cardiotoxic activities of Seocalcitol.
SiltuximabDeslanoside may decrease the cardiotoxic activities of Siltuximab.
SirolimusDeslanoside may decrease the cardiotoxic activities of Sirolimus.
SonidegibDeslanoside may decrease the cardiotoxic activities of Sonidegib.
SorafenibDeslanoside may decrease the cardiotoxic activities of Sorafenib.
SotalolSotalol may increase the bradycardic activities of Deslanoside.
SparfloxacinDeslanoside may decrease the cardiotoxic activities of Sparfloxacin.
Sparfosic acidDeslanoside may decrease the cardiotoxic activities of Sparfosic acid.
SparsomycinDeslanoside may decrease the cardiotoxic activities of Sparsomycin.
SpectinomycinThe serum concentration of Deslanoside can be decreased when it is combined with Spectinomycin.
SpironolactoneThe therapeutic efficacy of Deslanoside can be decreased when used in combination with Spironolactone.
squalamineDeslanoside may decrease the cardiotoxic activities of squalamine.
SRT501Deslanoside may decrease the cardiotoxic activities of SRT501.
StreptomycinThe serum concentration of Deslanoside can be decreased when it is combined with Streptomycin.
StreptozocinDeslanoside may decrease the cardiotoxic activities of Streptozocin.
StreptozocinThe serum concentration of Deslanoside can be decreased when it is combined with Streptozocin.
SulfasalazineThe serum concentration of Deslanoside can be decreased when it is combined with Sulfasalazine.
SulindacDeslanoside may decrease the cardiotoxic activities of Sulindac.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Deslanoside.
SunitinibDeslanoside may decrease the cardiotoxic activities of Sunitinib.
SuraminDeslanoside may decrease the cardiotoxic activities of Suramin.
SwainsonineDeslanoside may decrease the cardiotoxic activities of Swainsonine.
TamoxifenDeslanoside may decrease the cardiotoxic activities of Tamoxifen.
TegafurDeslanoside may decrease the cardiotoxic activities of Tegafur.
TelmisartanThe serum concentration of Deslanoside can be increased when it is combined with Telmisartan.
TemafloxacinDeslanoside may decrease the cardiotoxic activities of Temafloxacin.
TemozolomideDeslanoside may decrease the cardiotoxic activities of Temozolomide.
TemsirolimusDeslanoside may decrease the cardiotoxic activities of Temsirolimus.
TeniposideDeslanoside may decrease the cardiotoxic activities of Teniposide.
TestolactoneDeslanoside may decrease the cardiotoxic activities of Testolactone.
TetrathiomolybdateDeslanoside may decrease the cardiotoxic activities of Tetrathiomolybdate.
TezacitabineDeslanoside may decrease the cardiotoxic activities of Tezacitabine.
ThalidomideDeslanoside may decrease the cardiotoxic activities of Thalidomide.
ThiotepaDeslanoside may decrease the cardiotoxic activities of Thiotepa.
ThymalfasinDeslanoside may decrease the cardiotoxic activities of Thymalfasin.
TiboloneDeslanoside may decrease the cardiotoxic activities of Tibolone.
TimololTimolol may increase the bradycardic activities of Deslanoside.
TioguanineDeslanoside may decrease the cardiotoxic activities of Tioguanine.
TipifarnibDeslanoside may decrease the cardiotoxic activities of Tipifarnib.
TirapazamineDeslanoside may decrease the cardiotoxic activities of Tirapazamine.
TobramycinThe serum concentration of Deslanoside can be decreased when it is combined with Tobramycin.
TopotecanDeslanoside may decrease the cardiotoxic activities of Topotecan.
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Deslanoside.
ToremifeneDeslanoside may decrease the cardiotoxic activities of Toremifene.
TositumomabDeslanoside may decrease the cardiotoxic activities of Tositumomab.
TrabectedinDeslanoside may decrease the cardiotoxic activities of Trabectedin.
TrametinibDeslanoside may decrease the cardiotoxic activities of Trametinib.
TrastuzumabDeslanoside may decrease the cardiotoxic activities of Trastuzumab.
Trastuzumab emtansineDeslanoside may decrease the cardiotoxic activities of Trastuzumab emtansine.
TretinoinDeslanoside may decrease the cardiotoxic activities of Tretinoin.
TriamtereneThe therapeutic efficacy of Deslanoside can be decreased when used in combination with Triamterene.
TrichlormethiazideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Deslanoside.
TrifluridineDeslanoside may decrease the cardiotoxic activities of Trifluridine.
TrilostaneDeslanoside may decrease the cardiotoxic activities of Trilostane.
TrimetrexateDeslanoside may decrease the cardiotoxic activities of Trimetrexate.
TriptorelinDeslanoside may decrease the cardiotoxic activities of Triptorelin.
TrovafloxacinDeslanoside may decrease the cardiotoxic activities of Trovafloxacin.
TroxacitabineDeslanoside may decrease the cardiotoxic activities of Troxacitabine.
TTNPBDeslanoside may decrease the cardiotoxic activities of TTNPB.
TubercidinDeslanoside may decrease the cardiotoxic activities of Tubercidin.
UbenimexDeslanoside may decrease the cardiotoxic activities of Ubenimex.
Uracil mustardDeslanoside may decrease the cardiotoxic activities of Uracil mustard.
ValrubicinDeslanoside may decrease the cardiotoxic activities of Valrubicin.
VandetanibDeslanoside may decrease the cardiotoxic activities of Vandetanib.
VapreotideDeslanoside may decrease the cardiotoxic activities of Vapreotide.
VeliparibDeslanoside may decrease the cardiotoxic activities of Veliparib.
VemurafenibDeslanoside may decrease the cardiotoxic activities of Vemurafenib.
VerteporfinDeslanoside may decrease the cardiotoxic activities of Verteporfin.
VinblastineDeslanoside may decrease the cardiotoxic activities of Vinblastine.
VincristineDeslanoside may decrease the cardiotoxic activities of Vincristine.
VindesineDeslanoside may decrease the cardiotoxic activities of Vindesine.
VinorelbineDeslanoside may decrease the cardiotoxic activities of Vinorelbine.
VismodegibDeslanoside may decrease the cardiotoxic activities of Vismodegib.
Vitamin ADeslanoside may decrease the cardiotoxic activities of Vitamin A.
VorinostatDeslanoside may decrease the cardiotoxic activities of Vorinostat.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Steroid hormone binding
Specific Function:
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium ions, providing the energy for active transport of various nutrients.
Gene Name:
ATP1A1
Uniprot ID:
P05023
Molecular Weight:
112895.01 Da
References
  1. Zhao YN, Pan Y, Tao JL, Xing DM, Du LJ: Study on cardioactive effects of brazilein. Pharmacology. 2006;76(2):76-83. Epub 2005 Nov 24. [PubMed:16319518 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23